Q-omics provides the consensus-scored DSC1 profile across patient tissues and cancer cell-line models. DSC1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, DSC1 is differentially expressed in 12, with the highest sampling consensus in LUSC. Additionally, DSC1 RNA expression shows 14,048 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, LUSC, and TGCT as cancer lineages where DSC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DSC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DSC1 survival associations across molecular data types. DSC1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DSC1 RNA expression–survival associations across cancer types. High DSC1 expression shows unfavorable associations in KICH, BLCA, MESO, LUAD and THCA, but favorable associations in LAML. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for DSC1 RNA expression.
This table summarizes DSC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in LUSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DSC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DSC1 shows lower tumor expression in KICH, KIRP and BRCA and higher tumor expression in LUSC, HNSC and LUAD. The LUSC box plot shows higher DSC1 RNA expression in tumor versus normal tissue (log2 FC = +1.627, t-test p < 0.001).
This table shows molecular features associated with DSC1 in patient tissues and cancer cell lines. In patient samples, DSC1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DSC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BREAST and OESOPHAGUS.
